



For Immediate Release

October 30, 2024

## Sumitomo Chemical Announces Revisions to Its Financial Forecast for the Full Year Ending March 31, 2025

Based on recent performance trends, Sumitomo Chemical Co., Ltd. (hereinafter, the "Company") has made revisions to its consolidated financial forecast for the full year ending March 31, 2025, previously announced on April 30, 2024, as detailed below.

### Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2025

(Millions of yen)

	Sales Revenue	Core Operating Income *	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	2,670,000	100,000	70,000	20,000	12.23
Revised forecast (B)	2,600,000	100,000	180,000	25,000	15.28
Variance in amount (B-A)	(70,000)	-	110,000	5,000	
Variance in percentage (%)	(2.6)%	0.0%	157.1%	25.0%	
Results for the full year ended March 31, 2024	2,446,893	(149,049)	(488,826)	(311,838)	(190.69)

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

### Reasons for the Revision

As announced in the "Notice Regarding Sale of a Portion of the Shares Sumitomo Chemical Holds in Petro Rabigh, an Associate Accounted for Using the Equity Method, and Recording of Loss on Debt Waiver for a Loan to Petro Rabigh" on August 7, 2024, the Company and Saudi Arabian Oil Company (hereinafter, "Saudi Aramco") have agreed to waive existing revolving shareholder loans of US\$750 million each. Accordingly, the Company recorded a loss on debt waiver (finance expenses) and a share of profit of investments accounted for using the equity method (operating income: non-recurring factor) due to debt forgiveness. On the other hand, it is expected that losses derived from non-recurring factors, such as restructuring costs, will be reduced compared to previous forecast as the immediate-term, concentrated measures to improve business performance implemented company-wide are progressing smoothly. As a result, the consolidated financial results for FY2024 are expected to exceed the previous forecast in terms of operating income and net income attributable to owners of the parent.

### Cautionary Statement

Statements made in this document with respect to the Company's current plans, estimates, strategies and beliefs that are not historical facts are forward looking statements about the future performance of the Company. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; the Company's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

Information:

Financial Forecast by Segment for the Full Year Ending March 31, 2025

(Millions of yen)

		Fiscal 2024 Previous Forecast (A)	Fiscal 2024 Revised Forecast (B)	Variance in Amount (B-A)	Results for the Full Year ended March 31, 2024
Essential Chemicals & Plastics	Sales revenue	900,000	840,000	(60,000)	773,979
	Core operating income	(35,000)	(59,000)	(24,000)	(90,682)
Energy & Functional Materials	Sales revenue	290,000	270,000	(20,000)	300,264
	Core operating income	11,000	15,000	4,000	7,832
IT-related Chemicals	Sales revenue	410,000	420,000	10,000	414,150
	Core operating income	47,000	57,000	10,000	43,959
Health & Crop Sciences	Sales revenue	610,000	610,000	-	545,965
	Core operating income	62,000	62,000	-	30,892
Pharmaceuticals	Sales revenue	370,000	370,000	-	342,736
	Core operating income	3,000	3,000	-	(133,016)
Others / Adjustments	Sales revenue	90,000	90,000	-	69,799
	Core operating income	12,000	22,000	10,000	(8,034)
Total	Sales revenue	2,670,000	2,600,000	(70,000)	2,446,893
	Core operating income	100,000	100,000	-	(149,049)